Biogen’s Immunology Buying Spree Reveals a Strategy the Neurology Playbook Can No Longer Support
Biogen's $1B RayThera deal is its second major immunology acquisition in two years. A pipeline pivot this deliberate signals...
small molecule discovery
AI Rewires Drug Discovery’s Economics, Infrastructure, and Biology Itself
At BIO-Europe Spring 2026, leaders from Eli Lilly, Schrödinger, Boltz, Bioptimus, and Sofinnova Partners convened to diagnose how foundation...